EP1071327A4 - Autoantigenic fragments, methods and assays - Google Patents

Autoantigenic fragments, methods and assays

Info

Publication number
EP1071327A4
EP1071327A4 EP99919952A EP99919952A EP1071327A4 EP 1071327 A4 EP1071327 A4 EP 1071327A4 EP 99919952 A EP99919952 A EP 99919952A EP 99919952 A EP99919952 A EP 99919952A EP 1071327 A4 EP1071327 A4 EP 1071327A4
Authority
EP
European Patent Office
Prior art keywords
assays
methods
autoantigenic fragments
autoantigenic
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99919952A
Other languages
German (de)
French (fr)
Other versions
EP1071327A1 (en
Inventor
Nancy Thornberry
Antony Rosen
Livia Casciola-Rosen
Felipe A Andrade
Donald Nicholson
Sophie Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Merck and Co Inc
Johns Hopkins University
Original Assignee
Merck Frosst Canada and Co
Merck and Co Inc
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada and Co, Merck and Co Inc, Johns Hopkins University filed Critical Merck Frosst Canada and Co
Publication of EP1071327A1 publication Critical patent/EP1071327A1/en
Publication of EP1071327A4 publication Critical patent/EP1071327A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96436—Granzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Transplantation (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP99919952A 1998-04-22 1999-04-22 Autoantigenic fragments, methods and assays Withdrawn EP1071327A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8264398P 1998-04-22 1998-04-22
US82643P 1998-04-22
PCT/US1999/008774 WO1999053757A1 (en) 1998-04-22 1999-04-22 Autoantigenic fragments, methods and assays

Publications (2)

Publication Number Publication Date
EP1071327A1 EP1071327A1 (en) 2001-01-31
EP1071327A4 true EP1071327A4 (en) 2004-09-29

Family

ID=22172472

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99919952A Withdrawn EP1071327A4 (en) 1998-04-22 1999-04-22 Autoantigenic fragments, methods and assays

Country Status (5)

Country Link
EP (1) EP1071327A4 (en)
JP (1) JP2002511494A (en)
AU (1) AU3755199A (en)
CA (1) CA2329495A1 (en)
WO (1) WO1999053757A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0126144D0 (en) * 2001-10-31 2002-01-02 Syngenta Ltd Pesticidal formulations
WO2004073739A1 (en) * 2003-02-21 2004-09-02 Medvet Science Pty. Ltd. A method of diagnosis and treatment
PL3116887T3 (en) 2014-03-13 2021-09-06 Universität Basel Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein
JP6849667B2 (en) 2015-09-16 2021-03-24 ウニヴェルズィテート バーゼル Carbohydrate ligand that binds to antibodies against glycosphingolipid sugar chain epitopes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANDRADE F ET AL: "Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis.", IMMUNITY. APR 1998, vol. 8, no. 4, 1 April 1998 (1998-04-01), pages 451 - 460, XP002290799, ISSN: 1074-7613 *
FROELICH CHRISTOPHER J ET AL: "Granzyme B/perforin-mediated apoptosis of Jurkat cells results in cleavage of poly(ADP-ribose) polymerase to the 89-kDa apoptotic fragment and less abundant 64-kDa fragment", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 227, no. 3, 1996, pages 658 - 665, XP002290801, ISSN: 0006-291X *
See also references of WO9953757A1 *
SONG QIZHONG ET AL: "Interleukin-1-beta-converting enzyme-like protease cleaves DNA-dependent protein kinase in cytotoxic T cell killing", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 184, no. 2, 1996, pages 619 - 626, XP002290800, ISSN: 0022-1007 *

Also Published As

Publication number Publication date
JP2002511494A (en) 2002-04-16
CA2329495A1 (en) 1999-10-28
EP1071327A1 (en) 2001-01-31
AU3755199A (en) 1999-11-08
WO1999053757A1 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
GB9809839D0 (en) Antibody
IL128869A0 (en) Pyrozolopyrimidines and pyrazolotriazines
AU3185199A (en) Immunoassay device and method
GB0200425D0 (en) Methods and compositions fo assaying analytes
HUP0103473A3 (en) Phosphoglycolipid and methods for its use
AU8763098A (en) Immunoassay device
GB0007933D0 (en) Assays,methods and means
EP1079231A4 (en) Immunoassay reagents and immunoassay method
GB9815423D0 (en) Assays, therapeutic methods and means
GB9803425D0 (en) Microtome
EP1071327A4 (en) Autoantigenic fragments, methods and assays
GB9818915D0 (en) Antibodies
GB9828700D0 (en) Antibody
ZA200100234B (en) Immunoassay testing kit and containers.
GB9807848D0 (en) Assay method and means
GB2348701B (en) Assays,methods and means
AU2980799A (en) Lectomedin materials and methods
GB9813778D0 (en) Assay methods and means
AU5316099A (en) Prostate cancer assays and related methods
GB9825184D0 (en) Antigen
GB9827845D0 (en) Immunoassay or proteins
AU6415999A (en) Kappa-a conopeptides and uses therefor
AU2003252758B2 (en) Antibody variants and fragments thereof
GB9915075D0 (en) Assays,methods and means
AU3042999A (en) H.pylori antigen and its use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001122

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20001122;LT PAYMENT 20001122;LV PAYMENT 20001122;MK PAYMENT 20001122;RO PAYMENT 20001122;SI PAYMENT 20001122

A4 Supplementary search report drawn up and despatched

Effective date: 20040816

17Q First examination report despatched

Effective date: 20041004

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK FROSST CANADA LTD.

Owner name: JOHNS HOPKINS UNIVERSITY

Owner name: MERCK & CO., INC. (A NEW JERSEY CORP.)

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061005